Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Rofecoxib

Criteria

Inclusion Criteria:

• Resectable advanced stomach cancer (Tumour stage ≥ T2N1 according to the 5th edition of UICC staging system) without peritoneal or distant metastases.

• Normal renal function

Exclusion Criteria:

• Solid organ metastases

• Poor performance status

• Already on long-term aspirin or NSAID

• Renal or hepatic dysfunction

• Bleeding disorder

• Hypersensitive to COX-II inhibitors/aspirin/NSAID

• No history of myocardial infarct or stoke